What do systematic reviews say?

Rituximab vs placebo

Rituximab as 'first choice' showed no clear difference in mortality measured by clinical assessment over 28 months compared with placebo (low certainty).

• Rituximab for people with multiple sclerosis 2021 · Cochrane Headline outcomes only
  OR 0.25 [0.02, 2.77]
  1 study · 439 participants
  Low